

**Publikace in extenso:**

**Články v časopisech s IF (IF 450)**

1. Chyra Z, Sevcikova T, Vojta P, Puterova J, Brozova L, Growkova K, Filipova J, Zatopkova M, Grosicki S, Barchnicka A, Jedrzejczak WW, Waszczuk-Gajda A, Jungova A, Mikulasova A, Hajduch M, Mokrejs M, Pour L, Stork M, Harvanova L, Mistrik M, Mikala G, Robak P, Czyz A, Debski J, Usnarska-Zubkiewicz L, Jurczynszyn A, Stejskal L, Morgan G, Kryukov F, Budinska E, Simicek M, Jelinek T, Hrdinka M, Hajek R. Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. *Haematologica*. 2021 Feb 1;106(2):601-604.
2. Minarik J., Pika T., Radocha J., Jungova A., Straub J., Jelinek T., Pour L., Pavlicek P., Mistrik M., Brozova L., Krhovska P., Machalkova K., Jindra P., Spicka I., Plonkova H., Stork M., Bacovský J., Capkova L., Sykora M., Kessler P., Stejskal L., Heindorfer A., Ullrychova J., Skacel T., Maisnar V., Hajek R. Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice. *BMC Cancer*. 2021 Jan 15;21(1):73.
3. Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hajek R, Dimopoulos MA, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos MV, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*. 2021 Jan;35(1):31-44.
4. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. *Lancet Oncol*. 2021 Jan;22(1):142-154.
5. Kaiser M, Beksac M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. *Ann Hematol*. 2021 Jan;100(1):297-302.
6. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. *Blood Cancer J*. 2021 Feb 18;11(2):40.
7. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczynszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Housseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncol*. 2021 Mar;22(3):e105-e118.
8. Abigail Glaize Carey-Ewend, Shaye B. Hagler, Hunter Nicole Bomba, Morgan J. Goetz, Juli R. Bago, and Shawn D. Hingtgen. Developing Bio-Inspired 3D Models of Brain Cancer to Evaluate Tumor-Homing Neural Stem Cell Therapy. *Tissue Eng Part A*. 2021 Jul;27(13-14):857-866.

9. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U; EHA Guidelines Committee. Electronic address: [guidelines@ehaweb.org](mailto:guidelines@ehaweb.org); ESMO Guidelines Committee. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †. *Ann Oncol*. 2021 Mar;32(3):309-322.
10. Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. *Blood Cancer J*. 2021 Feb 1;11(2):24.
11. Benkova K, Mihalyova J, Hajek R, Jelinek T. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. *Blood Rev*. 2021 Mar;46:100758.
12. Lukáš Smolej, Peter Turcsányi, Zuzana Kubová, Jana Zuchnická, Jana Mihályová, Martin Šimkovič, Pavel Vodárek, Mária Krčméryová, Heidi Móciková, Martin Brejcha, Martin Špaček, Czech CLL Study Group, External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. *Br J Haematol*. 2021 Apr;193(1):133-137.
13. Mattia D'Agostino, Alessandra Larocca, Massimo Offidani, Anna Marina Liberati, Gianluca Gaidano, Maria Teresa Petrucci, Daniele Derudas, Andrea Capra, Renato Zambello, Nicola Cascavilla, Paolo de Fabritiis 9, Vanessa Innao, Francesca Bonello, Francesca Patriarca, Giulia Benevolo, Nicola Giuliani, Gabriele Aitoro, Tommasina Guglielmelli, Francesco Di Raimondo, Paolo Corradini, Pellegrino Musto, Roman Hájek, et al. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. *Blood Cancer J*. 2021 Apr 12;11(4):73.
14. Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W Auner, Xavier Leleu, Roman Hájek, et al. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. *J Hematol Oncol*. 2021 Apr 13;14(1):59.
15. Ivo Demel, Julio Rodriguez Bago, Roman Hajek and Tomas Jelinek. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020. *Br J Haematol*. 2021 May;193(4):705-722.
16. Fanfani, V., Zatopkova, M., Harris, A. L., Pezzella, F., & Stracquadanio, G. Dissecting the heritable risk of breast cancer: from statistical methods to susceptibility genes. *Semin Cancer Biol*. 2021 Jul;72:175-184.
17. Daniela Zackova, Hana Klamova, Petra Belohlavkova, Lukas Stejskal, Tereza Necasova, Lukas Semerad, Barbora Weinbergerova, Dana Srbova, Jaroslava Voglova, Petra Cicatkova, Zuzana Sustkova, Tomas Hornak, Jana Baranova, Jirina Prochazkova & Jiri Mayer. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. *Leuk Lymphoma*. 2021 Jan;62(1):194-202.
18. Lukáš Smolej, Yvona Brychtová, Eduard Cmunt, Michael Doubek, Martin Špaček, David Belada, Martin Šimkovič, Lukáš Stejskal, Irena Zygulová, Renata Urbanová, Martin Brejcha, Jana Zuchnická, Heidi Móciková, Tomáš Kozák, Czech CLL Study Group. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group. *Br J Haematol*. 2021 May;193(4):769-778.
19. Laura Rosiñol, Meral Beksac, Elena Zamagni, Niels W C J Van de Donk, Kenneth C Anderson, Ashraf Badros, Jo Caers, Michele Cavo, Meletios-Athanasios Dimopoulos, Angela Dispenzieri, Hermann Einsele, Monika Engelhardt, Carlos Fernández de Larrea, Gösta Gahrton, Francesca Gay, Roman Hájek, Vania Hungria, Artur Juczyszyn, Nicolaus Kröger, Robert A Kyle, Fernando Leal da Costa, Xavier Leleu, Suzanne Lentzsch, Maria V Mateos, Giampaolo Merlini, Mohamad Mohty, Philippe Moreau, Leo Rasche, Donna Reece, Orhan Sezer, Pieter Sonneveld, Saad Z Usmani, Karin Vanderkerken, David H Vesole, Anders Waage, Sonja Zweegman, Paul G Richardson, Joan Bladé. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *Br J Haematol*. 2021 Aug;194(3):496-507.
20. Roman Hájek, Jiří Minařík, Jan Straub, Luděk Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania Tm Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Bařinová, Matyáš Kuhn, Jiří Šilar, Lenka Čápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren, Vladimír Maisnar. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. *Future Oncol*. 2021 Jul;17(19):2499-2512.

21. Auner HW, Gavriatopoulou M, Delimpasi S, Simonova M, Spicka I, Pour L, Dimopoulos MA, Kriachok I, Pylypenko H, Leleu X, Doronin V, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD Jr, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Effect of Age and Frailty on the Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma. *Am J Hematol*. 2021 Jun 1;96(6):708-718.
22. Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2021 Jun 19;397(10292):2361-2371.
23. Motais B, Charvátová S, Walek Z, Hrdinka M, Smolarczyk R, Cichoń T, Czaplá J, Giebel S, Šimíček M, Jelínek T, Ševčíková T, Sobotka J, Kořístek Z, Hájek R, Bagó JR. Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. *Cells*. 2021 Apr 21;10(5):967.
24. Huvarová L, Kořístek Z, Jelínek T, Černá L, Smejkalová J, Navrátil M, Grebeníček L, Tvrda I, Michalíková M, Hájek R. Washing transplants with Sepax 2 reduces the incidence of side effects associated with autologous transplantation and increases patients' comfort. *Transfusion*. 2021 Aug;61(8):2430-2438.
25. Faith Davies, Robert Rifkin, Caitlin Costello, Gareth Morgan, Saad Usmani, Rafat Abonour, Antonio Palumbo, Dorothy Romanus, Roman Hajek, Evangelos Terpos, Dasha Cherepanov, Dawn Marie Stull, Hui Huang, Xavier Leleu, Jesus Berdeja, Hans C Lee, Katja Weisel, Michael Thompson, Mario Boccadoro, Jeffrey Zonder, Gordon Cook, Noemi Puig, Jorge Vela-Ojeda, Eileen Farrelly, Aditya Raju, Marlo Blazer, Ajai Chari. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. *Ann Hematol*. 2021 Sep;100(9):2325-2337.
26. Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryna Kriachok, Meletios A Dimopoulos, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P Venner, Mamta Garg, Don Ambrose Stevens, Hang Quach, Sundar Jagannath, Phillipe Moreau, Moshe Levy, Ashraf Badros, Larry D Anderson Jr, Nizar J Bahlis, Thierry Facon, Maria Victoria Mateos, Michele Cavo, Hua Chang, Yosef Landesman, Yi Chai, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G Kauffman, Sebastian Grosicki, Paul G Richardson. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. *Am J Hematol*. 2021 Sep 1;96(9):1120-1130.
27. Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, Massimo Offidani, Paolo Corradini, Andrea Capra, Alessandra Romano, Anna Marina Liberati, Donato Mannina, Paolo de Fabritiis, Nicola Cascavilla, Marina Ruggeri, Roberto Mina, Francesca Patriarca, Giulia Benevolo, Angelo Belotti, Gianluca Gaidano, Arnon Nagler, Roman Hájek, Andrew Spencer, Pieter Sonneveld, Pellegrino Musto, Mario Boccadoro, Francesca Gay. Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. *Clin Cancer Res*. 2021 Jul 1;27(13):3695-3703.
28. Stefania Oliva, Davine Hofste Op Bruinink, Lucie Rihova, Mattia D'Agostino, Lucia Pantani, Andrea Capra, Bronno van der Holt, Rossella Troia, Maria Teresa Petrucci, Tania Villanova, Pavla Vsianska, Romana Jugooa, Claudia Brandt-Hagens, Milena Gilestro, Massimo Offidani, Rossella Ribolla, Monica Galli, Roman Hajek, Francesca Gay, Michele Cavo, Paola Omedé, Vincent H J van der Velden, Mario Boccadoro, Pieter Sonneveld. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. *Blood Cancer J*. 2021 Jun 3;11(6):106.
29. Jakub Radocha, Tomas Jelinek, Ludek Pour, Ivan Spicka, Jiri Minarik, Tereza Popkova, Alexandra Jungova, Petr Pavlicek, Lucie Brozova, Martin Stork, Frantisek Sedlak, Petra Krhovska, Vladimir Maisnar, Adriana Heindorfer, Michal Sykora, Marek Wrobel, Peter Mikula, Petr Kessler, Jana Ullrychova, Roman Hajek. Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation. *Int J Lab Hematol*. 2021 Oct;43(5):e244-e247.
30. Viera Sandecká, Luděk Pour, Ivan Špička, Jiří Minařík, Jakub Radocha, Tomáš Jelínek, Adriana Heindorfer, Petr Pavlíček, Michal Sýkora, Alexandra Jungová, Petr Kessler, Marek Wróbel, David Starostka, Jana Ullrychová, Lukáš Stejskal, Martin Štork, Jan Straub, Tomáš Pika, Lucie Brožová, Sabina Ševčíková, Vladimír Maisnar, Roman Hájek. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. *Eur J Haematol*. 2021 Oct;107(4):466-474.

31. Larysa Sanchez, Xavier Leleu, Jennifer L Beaumont, Hailin Yu, Stacie Hudgens, Maryana Simonova, Holger W Auner, Hang Quach, Sosana Delimpasi, Ivan Špička, Luděk Pour, Iryna Kriachok, Meletios A Dimopoulos, Ganna Usenko, Roman Hájek, Reuben Benjamin, Dinesh Kumar Sinha, Christopher Venner, Thomas Illmer, Mamta Krishnan Garg, Don Ambrose Stevens, Sundar Jagannath, Moshe Levy, Larry D Anderson Jr, Nizar Jacques Bahlis, Thierry Facon, Michele Cavo, Yi Chai, Xiwen Ma, Shijie Tang, Hoyee Leong, Jatin Shah, Sharon Shacham, Michael Kauffman, Paul Richardson, Sebastian Grosicki. Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. *Am J Hematol*. 2021 Oct 1;96(10):E383-E386.
32. Andrea Knight, Lucie Rihova, Romana Kralova, Miroslav Penka, Zdenek Adam, Ludek Pour, Martin Piskacek, Roman Hajek. Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma. *J Clin Med*. 2021 Aug 20;10(16):3717.
33. Katarina Hradska, Roman Hajek, Tomas Jelinek. Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. *Front Pharmacol*. 2021 Aug 13;12:733890.
34. Davine Hofste op Bruinink, Stefania Oliva, Lucie Rihova, Alexander Schmitz, Milena Gilestro, Jeroen Te Marvelde, Romana Kralova, Helle Høholt, Annemiek Broijl, Hans Erik Johnsen, Roman Hajek, Mario Boccadoro, Pieter Sonneveld, Paola Omedè, Vincent H J Van der Velden. Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network. *Haematologica*. 2020 Oct 5;106(5):1496-1499.
35. Amina Kurtovic-Kozaric, Erna Islamagic, Adna Asic, Lejla Mehinovic-Cavcic, Larisa Besic, Hana Sahinbegovic, Hana Komic, Sabira Kurtovic, Lejla Burazerovic. A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina. *Acta Med Acad*. 2021 Apr;50(1):175-196.
36. Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, Van de Donk N, Terpos E, Broijl A, De Larrea CF, Gay F, Goldschmidt H, Hajek R, Vangsted AJ, Zamagni E, Zweegman S, Cavo M, Dimopoulos M, Einsele H, Ludwig H, Barosi G, Boccadoro M, Mateos MV, Sonneveld P, Miguel JS. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. *Haematologica*. 2021 Nov 1;106(11):2799-2812.
37. Mihályová J, Hradská K, Jelínek T, Motais B, Celichowski P, Hájek R. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. *Int J Mol Sci*. 2021 Oct 25;22(21):11470.
38. Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Víšek B, Ilhan O, Nadali G, Weinbergerová B, Córdoba-Masculano R, Marchetti M, Collins GP, Farina F, Cattaneo C, Cabirta A, Gomes-Silva M, Itri F, van Doesum J, Ledoux MP, Čerňan M, Jakšić O, Duarte RF, Magliano G, Omrani AS, Fracchiolla NS, Kulasekararaj A, Valković T, Poulsen CB, Machado M, Glenthøj A, Stoma I, Ráčil Z, Piukovics K, Navrátil M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). *J Hematol Oncol*. 2021 Oct 14;14(1):168.
39. Plášek J, Gumulec J, Máca J, Škarda J, Procházka V, Grézl T, Václavík J. COVID-19 Associated Coagulopathy: Mechanisms and Host-Directed Treatment. *Am J Med Sci*. 2021 Nov 6;S0002-9629(21)00403-1.
40. Renata Bezdekova, Tomas Jelinek, Romana Kralova, Martin Stork, Petra Polackova, Pavla Vsianska, Lucie Brozova, Jiri Jarkovsky, Martina Almasi, Ivanna Boichuk, Zdenka Knechtova, Miroslav Penka, Ludek Pour, Sabina Sevcikova, Roman Hajek, Lucie Rihova. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. *Br J Haematol* 2021; 195: 95–107.
41. Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Broijl A, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWJ, Offidani M, Palumbo GA, Spencer A, Boccadoro M, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. *J Clin Oncol*. 2021 Nov 10;39(32):3613-3622.
42. Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hajek R, Zozer N, Kastiris E, Broijl A, Schjesvold F, Boccadoro M, Terpos E. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. *Lancet Haematol*. 2021 Dec;8(12):e934-e946.

## Články v recenzovaných a ostatních časopisech

1. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Hemasphere*. 2021 Feb 3;5(2):e528.
2. Šušol O., Hájková B., Hájek R. et al. Prvních 50 COVID-19 pozitivních pacientů na Klinice hematologie Fakultní nemocnice Ostrava v roce 2020, *Transfuzie Hematol Dnes* 2021; 27(4): 323– 329.

## Kapitoly v knihách

1. Gumulec J. Trombóza centrálního žilního katétru, In: Hirmerová J et al. Trombóza a malignita. Praha: Rada Publishing 2021: 134-144. ISBN 978-80-271-3051-1.
2. Juraj Ďuraš, Michal Kaščák, Milan Navrátil, Roman Hájek. Ne-Hodgkinovy lymfomy, in KISS, Igor et al. Klinická onkologie pro mediky. Solidní nádory, nádory dětského věku a hematologické malignity. 3., Brno: Masarykova univerzita, 2021. ISBN 978-80-210-9908-1.
3. Juraj Ďuraš, Michal Kaščák, Milan Navrátil, Roman Hájek. Hodgkinův lymfom, in KISS, Igor et al. Klinická onkologie pro mediky. Solidní nádory, nádory dětského věku a hematologické malignity. 3., Brno: Masarykova univerzita, 2021. ISBN 978-80-210-9908-1.
4. J. Zuchnická, Netypický obraz čisté aplazie červené řady při indolentní lymfoproliferaci In Peter Rohoň a kol. HEMATOLOGIE A HEMATOONKOLOGIE V KAZUISTIKÁCH. Maxdorf, Praha, 2020, ISBN 978-80-7345-681-8, 253 s.
5. J. Zuchnická, Atypická pleomorfní varianta chronické lymfocytární leukemie In Peter Rohoň a kol. HEMATOLOGIE A HEMATOONKOLOGIE V KAZUISTIKÁCH. Maxdorf, Praha, 2020, ISBN 978-80-7345-681-8, 253 s.

## Postery:

1. Zuzana Chyra, Srikanth Talluri, Rao Prabhala, Mehmet Kemal Samur, Anil Aktas Samur, Yan Xu, Aaron Beeler, Roman Hajek, Mariateresa Fulciniti, Masood A. Shammas, Nikhil C. Munshi. Dysfunctional HDAC8 Impacts Genomic Integrity and is a Novel Therapeutic Target in Multiple Myeloma. ASH 12/2021, Atlanta
2. Šušol O., Hájková B., Hájek R.: Immune Response in 465 Hematological Patients Vaccinated with mRNA Vaccine Against Sars-Cov-2: A Single Centre Experience, ASH 12/2021, Atlanta  
Jelinek, Zihala, Sevcikova, Kapustova, Sahinbegovic, Sithara, Popkova, Plonkova, Broskevicova, Vrana, Zidlik, Koristek, Bago, Simicek, Hajek, Pathogenesis of extramedullary multiple myeloma: from resistance to identification of novel therapeutic targets. ASH 12/2021, Atlanta
3. Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Capkova L, Polackova P, Stork M, Knechtova Z, Venglar O, Jurczyszyn A, Castillo JJ, Penka M, Radocha J, Sevcikova S, Pour L, Rihova L and Hajek R. Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia. ASH 12/2021, Atlanta
4. Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanová, Lenka Capkova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Martin Mistrik, Jaroslav Bacovsky, Vladimir Maisnar, and Roman Hajek Follow-up analysis of ixazomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in routine clinical practice. ASH 12/2021, Atlanta
5. Juan-José Garcés, PhD, Noemi Puig, MD, PhD, Rosalinda Termini, María Teresa Cedena, MD, PhD, Cristina Moreno, José J Pérez, Diego Alignani, PhD, Sarvide Sarai, Albert Oriol, Esther González Garcia, MD, Fernando Escalante, MD, Anna Sureda, Felipe De Arriba, PhD, Rafael Rios, MD, PhD, Jose Maria Moraleda, MD, PhD, Mercedes Gironella, MD, Miguel T Hernández, MD, PhD, Juan Jose Joan Bargay, Luis Palomera, MD, PhD, Alberto Orfao, MD, PhD, Evangelos Terpos, MD, PhD, Albert Pérez, MD, Tomas Jelinek, Alexia Suárez, Hartmut Goldschmidt, Herve Avet-Loiseau, Aldo M. Roccaro, MD, PhD, Joaquin Martinez-Lopez, Juan Jose Lahuerta, MD, PhD, Enrique Ocio, Laura Rosinol, Joan Bladé Creixenti, Maria-Victoria Mateos, Jesus San-Miguel and Bruno Paiva, PhD. Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints, ORAL. ASH 12/2021, Atlanta

6. Zuzana Chyra, Mehmet Kemal Samur, Anil Aktas Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Daniel Woojun Park, Charles Y. Lin, Ryosuke Shirasaki, Constantine Mitsiades, Masood Shammas, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi. B Cell Transcriptional Coactivator POU2AF1 (BOB-1) is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma with Therapeutic Implication. ASH 12/2021, Atlanta
7. Sophia Adamia, Zuzana Chyra, Morgan OKeefe, Shruti Bhatt, Kenneth Wen, Geoffrey G. Fell, Yu-Tzu Tai, Marisa S Pioso, Ivane Abiatari, Anthony Letai, David M. Dorfman, Teru Hideshima, Kenneth C Anderson. Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma. ASH 12/2021, Atlanta
8. Ondrej Venglar, MSc, Tereza Sevcikova, Anjana Anilkumar Sithara, Veronika Kapustova, Jan Vrana, David Zihala, Ludmila Muronova, Lucie Huvarova, Lucie Broskevicova, Michal Simicek, Zdenek Koristek, Roman Hajek, MD, PhD and Tomas Jelinek, ASH 2021, Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma, ASH 12/2021, Atlanta
9. Leire Burgos, Luis Esteban Tamariz-Amador, MD, Noemí Puig, MD, PhD, María Teresa Cedena, MD, PhD, Tomas Jelinek, MD, PhD, Sarah K Johnson, PhD, Paolo Milani, MD, PhD, Lourdes Cordon, José J Pérez, Marta Lasa, Rosalinda Termini, Albert Oriol, MD, Miguel-Teodoro Hernández, MD, PhD, Luis Palomera, MD, PhD, Rafael Martinez Martinez, Javier de la Rubia, MD, PhD, Felipe De Arriba, PhD, Rafael Rios, MD, PhD, Maria Esther González, Mercedes Gironella, MD, Valentin Cabañas, MD, Maria Casanova, MD, Isabel Krsnik, Albert Pérez, MD, Veronica Gonzalez De La Calle, MD, PhD, Paula Rodríguez-Otero, MD, PhD, Vladimir Maisnar, MD, Roman Hajek, MD, PhD, Frits van Rhee, MD PhD, Victor H Jimenez-Zepeda, MD, Giovanni Palladini, Paolo Milani, Alberto Orfao, MD, PhD, Laura Rosinol, Joan Bladé Creixenti, Joaquín Martínez-López, Juan-José Lahuerta, MD, PhD, Maria-Victoria Mateos, Jesús F. San-Miguel and Bruno Paiva, PhD, Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies. ASH 12/2021, Atlanta
10. Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, MD, PhD, Arnaud Jaccard, Frank Bridoux, MD, Meletios A. Dimopoulos, MD, Sriram Ravichandran, MBBS, MRCP, FRCPath, Ute Hegenbart, MD, Wilfried Roeloffzen, M. Teresa Cibeira, MD, PhD, Hermine Agis, MD, Monique C. Minnema, MD, Rui Bergantim, Roman Hajek, MD, PhD, Cristina João, MD, PhD, MSc, Alexandros Leonidakis, PhD, Giorgos Cheliotis, MSc, Pieter Sonneveld, Efstathios Kastritis, MD and Ashutosh D. Wechalekar, MBBS MD. Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. ASH 12/2021, Atlanta
11. Nizar J. Bahlis, MD, Shambavi Richard, Darrell J. White, MD, Sebastian Grosicki, MD, PhD, Christine Chen, MHPE, MD, FRCPC, Sosana Delimpasi, MD, Heather J. Sutherland, MD, PhD, FRCPC, Zvenyslava Maslyak, MD, Michael Sebag, MD, PhD, Maria Gavriatopoulou, MD, Suzanne Lentzsch, MD, PhD, Ajai Chari, MD, Maryana Simonova, MD, Ivan Spicka, MD, Prof, PhD, Iryna Kriachok, Meletios A. Dimopoulos, MD, Halyna Pylypenko, MD, Holger W Auner, MD, PhD, Xavier Leleu, MD, Ganna Usenko, MD, Roman Hajek, MD, PhD, et al. Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). ASH 12/2021, Atlanta
12. Robert Z. Orłowski, Sosana Delimpasi, MD, Jan Straub, MD, Argiris Symeonidis, MD, PhD, Luděk Pour, MD, Roman Hajek, MD, PhD, et al. Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (dex; IDd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) with 1–3 Prior Therapies: Results of the Second Interim Analysis (IA2) of a Phase 2 Study. ASH 12/2021, Atlanta
13. Sundar Jagannath, MD, Thierry Facon, MD, Ashraf Z. Badros, MD, Moshe Levy, MD, Philippe Moreau, MD, PhD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD, Prof, PhD, Iryna Kriachok, Maria Gavriatopoulou, MD, Halyna Pylypenko, MD, Holger W Auner, MD, PhD, Xavier Leleu, MD, Vadim Doronin, MD, PhD, Ganna Usenko, MD, Roman Hajek, MD, PhD, et al. Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. ASH 12/2021, Atlanta
14. Roman Hájek, Tomas Jelinek, Philippe Moreau, Thomas Martin, Luděk Pour, Gábor Mikala, Argiris Symeonidis, Sara Bringhen, Andreea Rawlings, Marie-Laure Risse, Helgivan de Velde, Ivan Špička. Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma and Soft-Tissue Plasmacytomas: IKEMA Subgroup Analysis. IMW 9/2021
15. Jakub Radocha, Ivan Špička, Luděk Pour, Tomas Jelinek, Alexandra Jungova, Jiri Minarik, Adriana Heindorfer, Lukas Stejskal, Jana Ullrychova, Jarmila Obernauerova, Petr Kessler, Marek Wrobel, Petr Pavlíček, Michal Sykora, Peter Mikula, Vladimir Maisnar, Roman Hájek. COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients, IMW 9/2021

16. Renata Bezdekova, Tomas Jelinek, Martin Stork, Petra Polackova, Lucie Brozova, Martina Almasi, Ivanna Boichuk, Zdenka Knechtova, Miroslav Penka, Luděk Pour, Sabina Sevcikova, Lucie Rihova. IMPORTANCE OF FLOW CYTOMETRY ASSESSMENT OF CIRCULATING PLASMA CELLS AND ITS CONNECTION WITH CLINICAL CHARACTERISTICS OF PRIMARY AND SECONDARY PLASMA CELL LEUKEMIA, IMW 9/2021
17. Rosalinda Termini, David Žihala, Cirino Botta, Catarina Maia, Juan-Jose Garces, Evangelos Terpos, Albert Pérez-Montaña, Tomas Jelinek, Joan Bargay, Enrique M. Ocio, Jose Enrique de la Puerta, Joaquin Martinez-Lopez, Fernando Solano, Maria-Elena Cabezudo, Rebeca Iglesias, Antonio Garcia, Maria Casanova, Valentin Cabañas, Roman Hájek, Heinz Ludwig, Hartmut Goldschmidt, Hervé AvetLoiseau, Aldo Roccaro, Jesus F. San Miguel, Bruno Paiva. Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study. IMW 9/2021
18. Zuzana Chyra, Mehmet Kemal Samur, Anil Aktas Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Daniel Woojun Park, Charles Y. Lin, Ryosuke Shirasaki, Constantine Mitsiades, Masood Shammam, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi. B cell transcriptional coactivator POU2AF1 (BOB-1) modulates the protein synthesis and offers a potential vulnerability in multiple myeloma. IMW 9/2021
19. Zuzana Chyra, Morgan O'Keefe, Tereza Sevcikova, Roman Hajek, Kenneth Anderson, Sophia Adamia. Altered mRNA splicing identifies novel biomarkers and therapeutic targets in AL (Amyloid light-chain) Amyloidosis. IMW 9/2021
20. Huvarova L, Sevcikova T, Zihala D, Cerna L, Vrana J, Kapustova V, Venglar V, Jelinek T, Hajek R, Koristek Z. Transcriptome analysis of haematopoietic stem cells after mobilization with cytarabine and cyclophosphamide. EHA2021 Virtual Congress, 6/2021
21. Roman Hájek, Luděk Pour, Miquel Granell, Vladimir Maisnar, Paul G. Richardson, Stefan Norin, Malin Sydvanter, Jakob Obermüller, Enrique M. Ocio. ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—OPTIMAL DOSE AND UPDATED EFFICACY AND SAFETY RESULTS. EHA2021 Virtual Congress, 6/2021
22. Tomas Jelinek, Tereza Sevcikova, Tereza Popkova, Lucie Cerna, Lucie Broskevicova, Lucie Brozova, Lucie Rihova, Renata Bezdekova, Sabina Sevcikova, Hana Plonkova, Alexandra Jungova, Jiri Minarik, Ludek Pour, Petr Pavlicek, Ivan Spicka, Vladimir Maisnar, Jakub Radocha, Michal Simicek, Roman Hajek. LIMITED EFFICACY OF DARATUMUMAB IN MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE. EHA2021 Virtual Congress, 6/2021
23. Hradská K, Popkova T, Skorupova M, Mihalyova J, Jelinek T, Navratil M, Benkova K, Plonkova H, Zuchnicka J, Gumulec J, Hajek R. TELEMONITORING IN HAEMATO-ONCOLOGICAL PATIENTS: HIT OR MISS? 2nd European Myeloma Network Meeting, 3/2021
24. Hradská, Popková, Skořupová, Mihályová, Lančová, Schellong, Hájek, Uplatnění telemedicíny v hematookologické péči, Český hematologický a transfuziologický sjezd, Olomouc 9/2021